Black Diamond Therapeutics Statistics
Share Statistics
Black Diamond Therapeutics has 56.59M shares outstanding. The number of shares has increased by 9.41% in one year.
| Shares Outstanding | 56.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 42.91M |
| Failed to Deliver (FTD) Shares | 2.13K |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 6.40M, so 11.31% of the outstanding shares have been sold short.
| Short Interest | 6.40M |
| Short % of Shares Out | 11.31% |
| Short % of Float | 14.91% |
| Short Ratio (days to cover) | 13.52 |
Valuation Ratios
The PE ratio is -1.5 and the forward PE ratio is -2.66.
| PE Ratio | -1.5 |
| Forward PE | -2.66 |
| PS Ratio | 0 |
| Forward PS | 32.6 |
| PB Ratio | 1.06 |
| P/FCF Ratio | -1.85 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Black Diamond Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.82, with a Debt / Equity ratio of 0.
| Current Ratio | 6.82 |
| Quick Ratio | 6.82 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on capital (ROIC) is -60.87%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -0.52% |
| Return on Capital (ROIC) | -60.87% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.53M |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -20.57% in the last 52 weeks. The beta is 2.52, so Black Diamond Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.52 |
| 52-Week Price Change | -20.57% |
| 50-Day Moving Average | 2.53 |
| 200-Day Moving Average | 4.46 |
| Relative Strength Index (RSI) | 47.5 |
| Average Volume (20 Days) | 712.07K |
Income Statement
| Revenue | n/a |
| Gross Profit | -437.00K |
| Operating Income | -86.46M |
| Net Income | -82.44M |
| EBITDA | -86.02M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has 56.22M in cash and 25.30M in debt, giving a net cash position of 30.92M.
| Cash & Cash Equivalents | 56.22M |
| Total Debt | 25.30M |
| Net Cash | 30.92M |
| Retained Earnings | -417.43M |
| Total Assets | 137.90M |
| Working Capital | 94.74M |
Cash Flow
In the last 12 months, operating cash flow was -66.72M and capital expenditures -33.00K, giving a free cash flow of -66.75M.
| Operating Cash Flow | -66.72M |
| Capital Expenditures | -33.00K |
| Free Cash Flow | -66.75M |
| FCF Per Share | -1.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -83.93% |
| FCF Yield | -52.66% |
Analyst Forecast
The average price target for BDTX is $15.5, which is 592% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 592% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.08 |
| Piotroski F-Score | 2 |